Biocept Incorporated Company Profile

07:28 EDT 22nd June 2018 | BioPortfolio

Privately held Biocept was founded in 1997 and is based in Carlsbad, California near San Diego.

Biocept is emerging as a leader in the development and commercialization, in part through partners, of Next Generation Microarrays for Genomics and Proteomics™. Biocept’s proprietary platform technology is based on novel hydrogel polymers. The resulting three-dimensional microarrays have very high sensitivity, excellent precision and a broad dynamic range. Biocept has already developed several assay formats for the analysis of samples containing nucleic acids or proteins. Biocept has collaborations with investigators at leading research organizations for prototype microarrays to monitor the expression of apoptosis-related genes.

Life Sciences applications of Biocept’s genomic and proteomic microarrays include pharmaceutical research and development [e.g. target identification and validation, expression profiling, pathway analysis, high throughput screening, ADMET studies, and detection of single nucleotide polymorphisms (SNP's)] and clinical diagnostics.

Science & Technology:

Successful genomic and proteomic research requires tools that can rapidly and accurately provide results. While gene expression profiling is frequently the first step, protein expression may ultimately be more important, since proteins are the targets for most drugs. Gene expression does not always correlate well with the amount or activity of expressed proteins. In addition, protein diversity and activity results from alternative splicing at the messenger RNA level and by post-translational modifications such as phosphorylation and glycosylation. Several forms of a single protein may have important roles either as targets for drug discovery or as indicators of toxicity. These relationships demonstrate the crucial importance of proteomics in drug discovery.

Biocept's platform technology uses proprietary hydrogel polymers to create three-dimensional microarrays. Biocept prints microdroplets in an array on a treated glass slide. Each microdroplet contains a large number of molecules of a single probe, uniformly dispersed within and covalently bound to the hydrogel matrix. Key features of Biocept's microarrays are:

§ Versatile-useful for genomic and proteomic applications-

Biocept has developed and demonstrated the utility of genomic and proteomic microarrays in formats suitable for many life sciences applications.

§ High probe density provides high precision and broad dynamic range-

The higher probe density provides a lower coefficient of variation and broader dynamic range than conventional two-dimensional microarrays.

· Aqueous environment allows biomolecular probes to retain native conformation and activity-

Probes tethered within a hydrogel microdroplet retain their native three-dimensional configuration and activity, improving interaction with targets in the sample.

§ Readily manufactured-

Microdroplets about 300 microns in diameter and 30 microns thick are deposited as an array on a treated glass slide.

Biocept’s platform technology is protected by issued or pending patents in all major pharmaceutical markets.

Commercialization Strategy:

Biocept is establishing corporate partnerships and other collaborations to accelerate the development, commercialization and utilization of microarrays based on its technology. This includes partnerships with Pharmaceutical/Biotech companies for research and development, collaborations with Life Science Reagents companies, partnerships for clinical diagnostics, and partnerships to enhance technology development and commercialization.


2151 Las Palmas Drive, Suite C
United States of America


Phone: (760) 804-9580 x15
Fax: (760) 804-6238
Email: kbrown@biocept

News Articles [14 Associated News Articles listed on BioPortfolio]

Biocept announces pricing of $15M public offering

A public offering of common stock and stock purchase warrants has been priced by Biocept at $0.45 in hopes of raising $15 mil -More- 

Best efforts public offering nets $13.7mm for Biocept

Molecular diagnostics firm Biocept Inc. closed a best efforts public offering, netting $13.7mm through the sale of 32.85mm common shares at $0.45. (The company originally filed to sell 33.33mm shares....

Published Case Report Demonstrates the Clinical Utility of Biocept’s CTC Platform in Metastatic Breast Cancer

SAN DIEGO, June 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information t...

Biocept (BIOC) Presents At 30th Annual ROTH Conference - Slideshow

Biocept's (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call Transcript

Biocept's (BIOC) CEO Michael Nall on Q1 2018 Results - Earnings Call Transcript

Biocept Inc BIOC Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryBiocept Inc Biocept is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for vario...

Active-Investors: Free Post Earnings Research Report: Exact Sciences' Quarterly Revenues Jumped 148.02%

Stock Monitor: Biocept Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / has just released a free earnings report on Exact Sciences Corp. (NASDAQ: EXAS) ("EXAS"...

PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [40 Associated Companies listed on BioPortfolio]

Biocept, Inc.

Biocept is an emerging leader in genetic testing. The company's proprietary CEE™ Cell Enrichment and Extraction technology is designed to isolate and extract rare cells for highly accurate genetic a...

Biocept Incorporated

Privately held Biocept was founded in 1997 and is based in Carlsbad, California near San Diego. Biocept is emerging as a leader in the development and commercialization, in part through partners, of N...


PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...


Founded in 2008 by the Axis Biotec Brasil™ group (, PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....


COOK SIS is sold under various brand names to treat a wide range of conditions including management of dermal wounds and burns, reinforcement of many types of weakened tissue, and treatment of urinary...

More Information about "Biocept Incorporated" on BioPortfolio

We have published hundreds of Biocept Incorporated news stories on BioPortfolio along with dozens of Biocept Incorporated Clinical Trials and PubMed Articles about Biocept Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biocept Incorporated Companies in our database. You can also find out about relevant Biocept Incorporated Drugs and Medications on this site too.

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Corporate Database Quicklinks

Searches Linking to this Company Record